All news articles for July 2021

Pic:getty/kotofeja

AC Immune acquires Parkinson’s vaccine candidate

By Rachel Arthur

AC Immune will acquire Affiris’ portfolio of therapeutics targeting alpha-synuclein (a-syn), which includes a vaccine candidate for the treatment of Parkinson’s disease.

(RUNSTUDIO/iStock via Getty Images Plus)

CPHI NORTH AMERICA 2021

M&A activity vigorous in CDMO arena: CPhI

By Jenni Spinner

An expert speaking during the industry event offers insight and perspective on the flurry of CDMO deal-making in recent months, and what might lie ahead.

© GettyImages/Andrew Brookes

Generate looks to in-house stem cell manufacturing

By Jane Byrne

Generate Life Sciences is establishing a GMP facility in La Jolla, California that it says will enable end-to-end manufacturing of newborn stem cell biologics, bolstering supply and safeguarding clinical research.

© GettyImages/janiecbros

EU go-ahead for bluebird bio gene therapy for CALD

By Jane Byrne

Bluebird’s Lenti-D, or elivaldogene autotemcel, has won approval from the European Commission to treat children with a rare neurodegenerative disease called early cerebral adrenoleukodystrophy (CALD).

Pic:getty/adamgault

Biovac to manufacture Pfizer COVID-19 doses in Africa

By Rachel Arthur

South African biopharmaceutical company The Biovac Institute will manufacture and distribute Pfizer and BioNTech’s COVID-19 vaccine in Africa, with the three companies signing a letter of intent this week.

© GettyImages/FlashMovie

NPD Gallery: Technology Insider

By Jane Byrne

We report on some of the latest biopharma industry targeted new releases in terms of technological innovation.

Pic:getty/adamgault

Curia to acquire Integrity Bio

By Rachel Arthur

Curia, a contract research development and manufacturing organization, will acquire Californian formulation and fill-finish organization Integrity Bio.

© GettyImages/DNY59

FDA lead calls for independent inquiry into Biogen drug approval

By Jane Byrne

Acting US FDA commissioner, Janet Woodcock, has called for an independent federal review of interactions between officials at her agency and representatives of Biogen, prior to the recent approval of the pharma company’s treatment for Alzheimer’s disease....

Pic:getty/palto

Sartorius acquires majority stake in CellGenix

By Rachel Arthur

Sartorius is strengthening its product portfolio for cell and gene therapies with the acquisition of a majority stake in German reagent manufacturer CellGenix.